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Summary Objective: To evaluate the effects of hepatic
impairment on the pharmacokinetics and safety of a single,
oral axitinib dose in subjects with mild or moderate hepatic
impairment. Methods: In this phase I, open-label, parallel-
group study, a total of 24 subjects with either normal
hepatic function (n=8) or with mild (n=8) or moderate (n=
8) hepatic impairment were administered a single, oral dose
of axitinib (5 mg). Blood samples were collected at
intervals up to 144 h following dosing, and plasma
pharmacokinetics and safety were assessed. Changes in
axitinib plasma exposures in subjects with mild or moderate
hepatic impairment were predicted using computer simu-
lations and used to guide initial dosing in the clinical study.
Results: Axitinib exposure was similar in subjects with
normal hepatic function and those with mild hepatic
impairment, but approximately twofold higher in subjects
with moderate hepatic impairment. Axitinib exposure
weakly correlated with measures of hepatic function but
was not affected by smoking status. Axitinib protein
binding was similar in the three treatment groups. No
significant treatment-related adverse events were reported.
Conclusions: Compared with subjects with normal hepatic
function, moderate hepatic impairment increased axitinib
exposure, suggesting that the oral clearance of axitinib is
altered in these subjects. In addition, these data indicate a
possible need for a dose reduction in subjects who develop
moderate or worse hepatic impairment during axitinib
treatment. A single 5-mg dose of axitinib was well tolerated
in subjects with mild or moderate hepatic impairment.
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Introduction
Axitinib is an oral, potent, and selective inhibitor of
vascular endothelial growth factor (VEGF) receptors 1, 2,
and 3 [1]. Early clinical trial experience has demonstrated
that it has activity and is well tolerated as a single agent and
in combination with chemotherapy for the treatment of a
number of tumor types, including renal cell carcinoma [2,
3], thyroid cancer [4], and non-small cell lung cancer [5].
Axitinib is currently in phase III development for advanced
renal cell carcinoma.
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DOI 10.1007/s10637-010-9477-4In the clinic, axitinib is administered at a 5-mg twice-
daily, oral starting dose. The pharmacokinetics of axitinib
are linear within the 5–10 mg clinical-dose range as
assessed by single-dose administration in healthy volun-
teers and characterized by an oral absolute bioavailability of
58%, rapid oral absorption (with peak plasma concentra-
tions occurring 3–6 h after dosing in the fed state), and a
terminal phase plasma half-life (t1/2)o f3 –5h[ 6]. The
plasma protein binding of axitinib is >99%; in vitro studies
indicate that axitinib binds strongly to albumin and, to a
lesser extent, to α-1-acid glycoprotein (unpublished data).
Axitinib is metabolized primarily by oxidation via
cytochrome P450 (CYP) 3A4/5, and to a lesser extent by
CYP1A2, CYP2C19, and glucuronidation via the uridine
diphosphate-glucuronosyltransferase (UGT) 1A1 pathway
(unpublished data). In a human mass balance study, 30–
60% of the administered radiolabeled axitinib oral dose was
eliminated in feces, with renal elimination accounting for a
further 23% (unpublished data). No unchanged axitinib was
found in urine samples; all urinary radioactivity was related
to axitinib metabolites. Metabolic profiling of fecal samples
indicated that unchanged axitinib was the predominant
radioactive component. Together, these data indicate that
hepatobiliary excretion is the major elimination pathway
for axitinib. Thus, a clinical study to characterize changes
in axitinib exposure with hepatic impairment was war-
ranted. To assist in the design of the clinical study and to
select appropriate dosing, simulations were conducted using
the Simcyp® Population-based Absorption, Distribution,
Metabolism, and Excretion (ADME) Simulator (Simcyp®
Ltd, Sheffield, UK) [7] to predict changes in axitinib
plasma exposure in subjects with varying degrees of hepatic
impairment.
The primary objectives of the present phase I study were
to (1) evaluate the effect of hepatic impairment on axitinib
pharmacokinetics and (2) assess safety and tolerability of a
single oral 5-mg axitinib dose in subjects with mild or
moderate hepatic impairment. Since VEGF is central to one
of the target pathways for axitinib and plays a major role in
wound healing, subjects with severe hepatic impairment
were not included due to presumed mechanism-based risk
of bleeding events and coagulopathy.
Methods
Prestudy Simcyp simulation of the effect of hepatic
impairment on axitinib exposure
In order to assist in the development of the clinical study,
predictions of the effects of hepatic impairment on the
pharmacokinetics of axitinib were conducted using Simcyp
Population-Based ADME Simulator version 8.2 SP2. The
model for hepatic impairment was developed using parame-
ters obtained from preclinical assessments as well as built-in
software assumptions and standard physiological parameter
estimates. Plasma concentrations expected after administra-
tion of a single 5-mg oral dose of axitinib in subjects with
normal hepatic function or mild or moderate hepatic impair-
mentweresimulatedintenclinicaltrials(withtensubjectsper
clinical trial) under fed conditions using a one-compartmental
distribution and first-order absorption model.
Input parameters specific to axitinib estimated in vitro
included the apparent intrinsic clearance for each recombi-
nant CYP isoform: CYP3A4 (maximum velocity [Vmax]:
9.6 pmol/min/pmol of isoform; Michaelis-Menten constant
[Km]: 4 μM), CYP3A5 (Vmax: 1.41 pmol/min/pmol of
isoform; Km: 1.9 μM), CYP2C19 (Vmax: 0.11 pmol/min/
pmol of isoform; Km : 5.9 μM), and CYP1A2 (apparent
intrinsic clearance: 0.17 μL/min/pmol of isoform); the Vmax
and Km for UGT1A1 (132.5 pmol/min/mg of microsomal
protein and 44.2 μM, respectively); fraction unbound in
plasma (0.010); blood-to-plasma partition coefficient
(0.79); fraction absorbed (1.0);—Log10 dissociation con-
stant (4.2); absorption rate (1.98 L/h); and volume under
steady state conditions (1 L/kg). Based on observations
from a human mass balance study (unpublished data), the
renal clearance for axitinib was assigned a value of zero.
The Simcyp hepatic-impairment model assumes that the
activity of CYP isoforms decreases with worsening hepatic
function, specifically, that the activity of CYP3A4/5 is
decreased by 42% and 62% in mild and moderate hepatic
impairment, respectively, compared with normal hepatic
function.
Study design
This phase I, open-label, single-dose, parallel-group study
assessed the pharmacokinetics, safety, and tolerability of a
5-mg single oral dose of axitinib in subjects with normal
hepatic function or mild or moderate hepatic impairment
according to the US Food and Drug Administration (FDA)
guidelines on hepatic impairment studies [8]. The study
was carried out at two centers (Orlando, FL, and Miami,
FL) from May 16, 2008, to October 26, 2008.
Subjects
Participants were male or female subjects aged≥18 years with
normal hepatic function or mild or moderate hepatic impair-
ment, according to the Child-Pugh (CP) classification [9, 10].
Subjects were screened for participation within 21 days prior
to the first dose of study treatment. Subjects with normal
hepatic function were recruited after subjects with mild (CP
class A [CP-A] score 5–6) and moderate (CP class B [CP-B]
score 7–9) hepatic impairment had completed the study. In
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Control subjects with normal hepatic function were matched
to subjects with hepatic impairment based first on weight,
and then on age and gender. In order to match subjects based
on body weight, four of the subjects with normal hepatic
function were matched to four subjects in each of the mild
and moderate hepatic-impairment groups. Individual subjects
to match were those with the lowest (n=1), highest (n=1),
and median (n=2) weights (±10 kg) in each hepatic-impaired
group. After matching subjects with normal hepatic function
by body weight, they were then matched for age (±10 years)
and gender to subjects with mild or moderate hepatic
impairment.
Subjects with normal hepatic function were required to be
healthy, defined as no clinically relevant abnormalities, which
were identified by a detailed medical history and full physical
examination, including blood pressure, pulse rate, 12-lead
electrocardiogram (ECG), and clinical laboratory tests. Liver
functiontests,albumin,andprothrombintimewereallrequired
to be within normal range. Eligible subjects had a body mass
index (BMI) of 18–32 kg/m
2 and a total body weight >50 kg.
Subjects with hepatic impairment were required to have
hepatic dysfunction due to hepatocellular disease (not
secondary to other diseases) as documented by medical
history, physical examination, liver biopsy, hepatic ultra-
sound, computed tomography scan, or magnetic resonance
imaging, and have adequate renal function, determined by a
24-h creatinine clearance >75 ml/min. Hepatic dysfunction
w a sr e q u i r e dt ob es t a b l e ,d e f i n e da sn oc l i n i c a l l y
significant change in disease status within the last 30 days,
which was documented by recent medical history, including
no worsening of clinical signs of hepatic impairment or no
worsening of total bilirubin or prothrombin time >50%.
Subjects with hepatic impairment also had to be on a stable
treatment regimen or dose of medication, or a fluctuating
treatment regimen if the underlying disease was under
control, provided sponsor approval was granted prior to the
first dose of study treatment. In addition to the general
exclusion criteria for all groups outlined below, exclusion
criteria specific to subjects with hepatic impairment
included any other clinically significant diseases that
contraindicated the use of axitinib or may have affected
its pharmacokinetics; the use of food or prescription or non-
prescription drugs that are potent inducers or inhibitors of
CYP3A4/5 within 7 days or 5 half-lives (whichever was
longer) prior to dosing; any clinically significant laboratory
abnormality, except for those parameters influenced by
hepatic impairment; or significant hepatic encephalopathy
(grade>2 portal systemic encephalopathy score and severe
ascites and/or pleural effusion).
Exclusion criteria for subjects in all groups included a
history of febrile illness≤5 days prior to dosing; any
condition, such as gastrectomy, that could affect drug
absorption; 12-lead ECG demonstrating corrected QT
interval >450 msec in healthy subjects (i.e., normal hepatic
function) and >470 msec in subjects with mild or moderate
hepatic impairment at screening; a history of regular
alcohol consumption (>7 drinks/week for females or >14
drinks/week for males) within 6 months of screening; and
the use of prescription or non-prescription drugs (except
acetaminophen≤1 g/day), vitamins, or dietary supplements
within 7 days or 5 half-lives (whichever was longer) prior
to dosing in the normal hepatic-function group. Herbal
supplements and hormone replacement therapy were to
have been discontinued 28 days prior to dosing. Female
subjects of childbearing potential, including those with
tubal ligation, were not included in the study.
All subjects were required to abstain from grapefruit-
containing products for 7 days prior to and during the study
until collection of the final blood sample for pharmacoki-
netic analysis, strenuous exercise 48 h prior to and during
the study, and alcohol and caffeine consumption 24 h prior
to and during the study. The use of tobacco- or nicotine-
containing products equivalent to ≤5 cigarettes/day was
permitted throughout the study period.
This study was performed in accordance with ethical
principles originating in or derived from the Declaration of
Helsinki and in compliance with the International Confer-
ence on Harmonization Good Clinical Practice guidelines
and applicable local regulatory requirements and laws. An
Institutional Review Board approved the protocol, and all
participants gave written informed consent. This trial was
registered on ClinicalTrials.gov (NCT00692341).
Axitinib administration
Subjects with hepatic impairment were admitted to the
clinical research unit 2 days before dosing (day-1) in order
to obtain a baseline 24-h urine collection for accurate
assessment of renal function. Subjects with normal hepatic
function were admitted the day before dosing (day 0).
Subjects fasted for ≥10 h prior to consumption of a
standardized meal on day 1. The standardized meal consisted
of 30% fat, 15% protein, and 55% carbohydrate, equivalent
to 500–700 calories, and represented a typical meal
consumed by an oncology patient. Subjects received a 5-
mg single oral dose of axitinib administered as a film-coated
immediate-release, dry-granulated tablet within 30 min of
the start of the meal with 240 ml of water. All subjects were
required to remain within the clinical research unit until day
3 and return for follow-up visits on days 5 and 7.
Evaluation of axitinib pharmacokinetics
Blood samples (5 ml) were collected in K3-EDTA antico-
agulant tubes at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36,
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on day 1. Separate blood samples (10 ml) in K3-EDTA
anticoagulant were also collected on day 1 (0 and 4 h after
dosing) for measurement of protein binding of axitinib in
plasma. Blood samples for axitinib protein binding were
initially scheduled to be collected 0 and 1–2 h after axitinib
dosing (pre- and post-dosing, respectively). However, the
observed time to maximum observed concentration of
axitinib was delayed in patients with hepatic impairment
(occurring 4 h after dosing). Thus, blood samples collected
0 and 4 h after dosing were used to determine protein
binding of axitinib in plasma. To protect from photo-
degradation, axitinib in all blood and plasma samples was
protected from visible and ultraviolet light exposure during
collection, storage, processing, and analysis. Plasma sam-
ples were analyzed for axitinib using a high-performance
liquid chromatography with tandem mass spectrometric
(LC/MS/MS) detection method (Charles River Laborato-
ries, Shrewsbury, MA) validated for accuracy, precision,
sensitivity, selectivity, matrix effects, recovery, and stability
in compliance with Pfizer standard operating procedures,
which conform to the requirements of the FDA bioanalytical
method validation guidance [11], as well as a subsequent
bioanalytical white paper generated by the FDA and industry
representatives [12]. The standard curve was linear with
weighted (1/concentration
2) regression and included nine
concentrations in duplicate (range 0.5–100 ng/ml). Each
individual standard was within 12% of nominal concentra-
tion, and inter-assay precision at each standard level was
within 4% coefficient of variation (CV). Duplicate quality
control (QC) samples at four concentration levels spanning
the assay range (1.5, 7.0, 40, and 80 ng/ml) were included
in each analytical run to measure assay acceptance. At
each QC level, inter-assay accuracy was within 6% of
nominal concentration and inter-assay precision was within
6% CV.
Plasma samples were fortified with deuterium-labeled
(d7) axitinib internal standard (IS), followed by addition of
1 M sodium bicarbonate. The samples were extracted with
ethyl acetate:hexanes (75:25, v/v), centrifuged, and the
supernatants were evaporated to dryness under a gentle
nitrogen stream in a TurboVap® (Caliper Life Sciences Inc,
Waltham, MA) heated to 45°C. Sample residues were
reconstituted in water/methanol/sodium bisulfite/ascorbic
acid (75:25:0.5:0.5, v/v/v/v) and eluted from a pentafluor-
ophenylpropyl (F5) column (Discovery HS F5, 50×
2.1 mm, 5 μm [Supelco, Bellefonte, CA]) using a gradient
of 20–80% B over 3 min (mobile phase A=10 mM
ammonium acetate, mobile phase B=acetonitrile) at a
0.5 ml/min flow rate onto an API 3000® mass spectrometer
(AB Sciex™, Concord, Ontario, Canada) with electrospray
ionization source. Detection was in positive ion mode with
multiple reaction monitoring (mass transitions m/z 387→
356 for axitinib and 394→360 for axitinib-d7). Peak areas
were quantitated using Analyst® software (AB Sciex™,
Concord, Ontario, Canada).
Standard axitinib pharmacokinetic parameters were
estimated using non-compartmental methods with Pfizer
proprietary software (eNCA). Pharmacokinetic parameters
assessed were area under the plasma concentration-time
curve (AUC) from time zero to infinity AUC0 1 ðÞ , AUC
from time zero to time of the last measurable concentration
(AUC0-last), maximum observed plasma concentration
(Cmax), time to Cmax,t 1/2, apparent oral clearance (CL/F),
and apparent volume of distribution (Vz/F).
Evaluation of axitinib protein binding
Plasma samples were processed to determine axitinib
protein binding using an equilibrium dialysis method, and
concentrations of resulting unbound and bound axitinib
were measured by high-performance LC/MS/MS detection
methods (Charles River Laboratories, Shrewsbury, MA)
validated in compliance with Pfizer standard operating
procedures. Dialysis was performed in a 96-well Teflon
dialysis plate (Equilibrium Dialysis Device HTD 96;
HTDialysis LLC, Gales Ferry, CT) with wells divided by
Spectra/Por®-regenerated cellulose membranes with a
molecular weight cut-off of 12,000–14,000 Da (Spectrum®
Laboratories, Rancho Dominguez, CA). Plasma samples
were dialyzed in duplicate against equal volumes of
phosphate-buffered saline (70 mM sodium chloride,
50 mM sodium phosphate, pH 7.4) for approximately
20 h at 37°C with orbital shaking at 80 rpm. Axitinib
concentrations in plasma dialysate (representing total bound
and unbound axitinib) were measured with the LC/MS/MS
assay used for plasma pharmacokinetic samples. Each
individual standard was within 10% of nominal concentra-
tion and intra-assay precision at each standard level was
within 8% CV. At each QC level, intra-assay accuracy was
within 9% of nominal concentration and intra-assay
precision was within 6% CV.
Axitinib concentrations in buffer dialysate (representing
unbound axitinib) were measured using a validated LC/MS/
MS assay in K3-EDTA plasma “water”, an aqueous layer of
the supernatant generated by high-speed ultracentrifugation
of plasma [13] (440,000×g for 2.5 h at 37°C) using a
Beckman TL100 Micro UltraCentrifuge (Beckman Coulter
I n c ,B r e a ,C A ) .T h ep l a s m a“water” assay had been
developed previously and was considered fit-for-purpose
for buffer dialysate study sample analysis due to matrix
similarity. The standard curve was linear with weighted
(1/concentration
2) regression and included nine concentra-
tions in duplicate (range 20–1,000 pg/ml). Each acceptable
individual standard was within 13% of nominal concentra-
tion, and intra-assay precision at each standard level was
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Duplicate QC samples at three concentration levels span-
ning the assay range (60, 150, and 800 pg/ml) were
included in each analytical run to measure assay accep-
tance. At each QC level, intra-assay accuracy was within
6% of nominal concentration and intra-assay precision was
within 1% CV. In addition, QCs consisting of dialyzed
plasma:dialyzed buffer (1:1, v/v) at concentrations
corresponding to low and high areas of the standard curve
(n=6 at 60 and 800 pg/ml) were included to determine
whether the matrix difference between standards and study
samples affected quantitation accuracy. For the mixed
plasma:buffer QCs, intra-assay accuracy was within 2% of
nominal concentration and intra-assay precision was within
3% CV at each QC level.
Buffer dialysate samples were fortified with axitinib-d7 IS,
followed by addition of 1 M sodium bicarbonate and 10 mM
ammonium acetate aqueous solution (aq). The samples were
extracted with ethyl acetate:hexanes (75:25, v/v), centrifuged,
and the supernatants were evaporated to dryness under a
gentle nitrogen stream in a TurboVap heated to 45°C. Sample
residues were reconstituted in water/methanol/sodium
bisulfite/ascorbic acid (75:25:0.5:0.5, v/v/v/v) and eluted
isocratically with 10 mM ammonium acetate (aq):acetonitrile
(60:40, v/v) mobile phase over 2 min from a pentafluorophe-
nylpropyl(F5)column(DiscoveryHSF5,50×2.1mm,5μm)
at a 0.5 ml/min flow rate onto an API 4000™ mass
spectrometer (AB Sciex™, Concord, Ontario, Canada) with
electrospray ionization source. Detection was in positive ion
mode with multiple reaction monitoring (mass transitions m/z
387→356 for axitinib and 394→360 for axitinib-d7). Peak
areas were quantitated using Analyst software.
Fraction unbound (fu) was calculated as axitinib in buffer
dialysate (ng/ml) / (axitinib in plasma dialysate [ng/ml]+
axitinib in buffer dialysate [ng/ml]). Mean fu for each
sample was used to calculate pharmacokinetic parameters.
Unbound axitinib pharmacokinetic parameters assessed
included unbound AUC0 1 and AUC0-last (calculated as
AUC0 1 *f uand AUC0-last *f u , respectively), Cmax
unbound (calculated as Cmax *f u ), unbound CL/F (calculated
as CL/F / fu), and unbound Vz/F (calculated as Vz/F / fu).
Safety evaluation
Safety assessments included recording of adverse events,
ECGs, blood pressure, pulse rate, clinical laboratory tests
(including liver and renal function tests, prothrombin time,
and partial thromboplastin time), physical examinations,
and vital signs. Blood pressure and pulse rate were
measured at screening, pre-dose on day 1, and at 1, 2, 16,
and 144 h post dose. A single standard 12-lead ECG was
obtained at screening, post dose on day 1, and at 1.5, 48,
and 144 h post dose.
Statistical methods
Sample size was based on recommendations from the FDA
Guidance for Industry on hepatic impairment studies [8].
Pharmacokinetic parameters were estimated by using non-
compartmental methods as described above, and summa-
rized by descriptive statistics. Using one-way analysis of
variance (ANOVA), natural log-transformed pharmacoki-
netic parameters (AUC0 1, AUC0-last, and Cmax) were
compared between the group of subjects with normal
hepatic function and each group of subjects with hepatic
impairment. Point estimates and 90% confidence intervals
(CIs) for the differences between these groups on the log
scale were constructed then back-transformed to provide
estimates of the ratio of adjusted geometric means (i.e.,
moderate hepatic impairment/normal function and mild
hepatic impairment/normal function) and 90% CIs for the
ratios. The differences in pharmacokinetic parameters
between subjects with hepatic impairment and with normal
hepatic function were evaluated by examination of the
ratios and 90% CIs. Relationships between axitinib expo-
sure and laboratory components of CP score, including
bilirubin, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), albumin, and prothrombin time, were
assessed graphically and by simple linear regression.
Results
Predictions from Simcyp modeling
Using the hepatic impairment model in Simcyp, it was
predicted that mild hepatic impairment would increase the
axitinib AUC0 1,a n dC max by 1.31- and 1.05-fold,
respectively, compared with normal hepatic function. When
axitinib pharmacokinetics in moderate hepatic impairment
subjects was simulated, Simcyp predicted a 1.52- and a 1.08-
fold increase in AUC0 1 and Cmax, respectively, compared
with normal hepatic function. The axitinib CL/F predicted for
subjects with normal hepatic function by Simcyp modeling
using clearance parameters from in vitro experiments with
recombinant CYPs was ∼8 L/h, which is approximately
threefold lower than what is observed clinically. The
predicted 1.52-fold increase in AUC did not warrant the
use of a lower axitinib dose in subjects with moderate
hepatic impairment compared with those with normal hepatic
function given the observed six-fold variability in a
previously published healthy volunteers study [14].
Subjects
A total of 24 subjects (n=20 male, 4 female) with a mean
age of 51.3 years (range 39.0–60.0) and with normal
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hepatic function (n=8) or mild (n=8) or moderate (n=8)
hepatic impairment were enrolled in this study. Subject
demographics are summarized in Table 1. The mean height,
weight, and BMI of all subjects were 89.0 kg (range 60.0–
115.4), 175.3 cm (range 156.0–188.0), and 28.9 kg/m
2
(range 23.9–32.7), respectively. The healthy-subject group
was comparable to the two hepatic-impairment groups with
respect to weight, age, and gender. All subjects received the
5-mg single oral dose of axitinib and were eligible for
pharmacokinetic and safety analysis. There were no
discontinuations or withdrawals from the study.
Pharmacokinetics
The observed clinical plasma pharmacokinetic parameters
of axitinib in patients with normal hepatic function or mild
or moderate hepatic impairment are summarized in Table 2
and Fig. 1. The plasma concentration-time curves by
treatment group are shown in Fig. 2. Overall, subjects with
mild hepatic impairment had similar axitinib pharmacoki-
netics to those with normal hepatic function. However,
axitinib exposure was higher among subjects with moderate
hepatic impairment compared with subjects with normal
hepatic function, as indicated by geometric mean AUC0 1
(304 ng h/ml [%CV 44] vs. 156 ng h/ml [%CV 63],
Table 1 Subject baseline demographics
Normal hepatic
function
Mild hepatic
impairment
Moderate
hepatic
impairment
(n=8) (n=8) (n=8)
Male/female,
n (%)
7 (87.5)/1
(12.5)
7 (87.5)/1
(12.5)
6 (75.0)/2
(25.0)
Age, y
Mean (SD) 47.4 (5.2) 52.5 (5.6) 54.3 (4.7)
Range 39–54 42–58 45–60
Ethnicity, n (%)
Black 2 (25.0) 0 1 (12.5)
White 6 (75.0) 8 (100.0) 7 (87.5)
Weight, kg
Mean (SD) 87.4 (14.4) 89.4 (8.3) 90.3 (13.9)
Range 60.0–105.9 76.3–100.0 68.2–115.4
Height, cm
Mean (SD) 172.0 (8.0) 175.9 (6.3) 178.0 (9.1)
Range 156.0–184.0 162.6–183.0 159.0–188.0
Body mass index, kg/m
2
Mean (SD) 29.3 (2.8) 28.9 (2.4) 28.4 (3.0)
Range 24.7–32.6 24.1–30.8 23.9–32.7
Abbreviation: SD standard deviation
Table 2 Pharmacokinetic parameters of axitinib following administration of a single 5-mg oral dose in subjects with normal hepatic function or
mild or moderate hepatic impairment
Pharmacokinetic parameter Normal hepatic function Mild hepatic impairment Moderate hepatic impairment
(n=8) (n=8) (n=8)
AUC0 1 (ng h/ml)
a 156 (63) 122 (167) 304 (44)
AUC0-last (ng h/ml)
a 148 (69) 116 (180) 295 (44)
CL/F (L/hr)
a 32.1 (63) 40.9 (167) 16.4 (44)
Cmax (ng/ml)
a 30.4 (50) 27.0 (127) 38.8 (50)
Tmax (h)
b 3.5 (2.0–4.0) 2.75 (1.0–4.0) 4.0 (1.5–4.0)
Vz/F (L)
a 166 (52) 163 (87) 128 (67)
t½ (h)
c 4.74 (80) 3.61 (84) 7.12 (91)
Fraction unbound
a 0.004049 (25) 0.002987 (50) 0.004083 (134)
AUC0 1;unbound (ng h/ml)
a 0.630 (56) 0.689 (82) 1.241 (109)
AUC0-last, unbound (ng h/ml)
a 0.601 (61) 0.671 (81) 1.206 (106)
Cmax, unbound (ng/ml)
a 0.123 (46) 0.132 (47) 0.159 (97)
CL/F unbound (L/hr)
a 7933 (56) 7253 (82) 4029 (109)
Vz/F unbound (L)
a 41,109 (57) 42,378 (40) 31,269 (121)
Abbreviations: AUC0 1 area under the concentration-time curve (AUC) from time zero to infinity, AUC0–last AUC from time zero to time of the
last measurable concentration, AUC0 1;unbound AUC for unbound drug from time zero to infinity, AUC0–last, unbound AUC for unbound drug from
time zero to time of the last measurable concentration, CL/F, apparent oral clearance, CL/Funbound apparent oral clearance of unbound drug,
Cmax maximum observed plasma concentration, Cmax, unbound maximum observed plasma concentration for unbound drug, t1/2 half life, Tmax time
to maximum observed plasma concentration, Vz/F apparent volume of distribution, Vz/Funbound apparent volume of distribution for unbound drug
a Geometric mean (% coefficient of variation [CV] around the geometric mean)
b Median (range)
c Arithmetic mean (% CV around the arithmetic mean)respectively) and Cmax (38.8 ng/ml [%CV 50] vs. 30.4 ng/ml
[%CV 50]), respectively.
Log-transformed pharmacokinetic parameters were com-
pared using ANOVA. The adjusted geometric means ratio
for AUC0 1 and Cmax in subjects with mild hepatic
impairment compared with normal hepatic function was
78.34% (90% CI 39.92–153.75) and 88.61% (90% CI
49.20–159.56), respectively. The adjusted geometric means
ratio for AUC0 1 and Cmax in subjects with moderate
hepatic impairment compared with normal hepatic function
was 195.25% (90% CI 99.49–383.18) and 127.67% (90%
CI 70.90–229.91), respectively.
Protein binding
Results of the protein-binding analysis are summarized in
Table 2. Approximately 0.3% to 0.4% of axitinib was
unbound in plasma in the subjects with varying hepatic
function assessed in this study. The geometric means for the
fraction unbound in plasma for axitinib were similar among
treatment groups. The adjusted geometric mean ratio for
fraction unbound in subjects with mild hepatic impairment
compared with normal hepatic function was 73.78% (90%
CI 37.40–145.56). The adjusted geometric mean ratio for
fraction unbound in subjects with moderate hepatic impair-
ment compared with normal hepatic function was 100.86%
(90% CI 55.58–183.02).
Overall, the results for the unbound pharmacokinetic
parameters mimicked those for total pharmacokinetic
parameters (Table 2). The axitinib geometric mean (%CV
for geometric mean) plasma Cmax, unbound values were
similar in subjects with normal hepatic function and mild
hepatic impairment. Likewise, axitinib geometric mean
plasma AUC0 1; unbound values and geometric mean
AUC0-last, unbound parameter estimates were similar in sub-
jects with normal hepatic function and mild hepatic
impairment, but were higher in those with moderate hepatic
impairment (Table 2).
Clinical correlations of laboratory parameters
The relationship between axitinib exposure and laboratory
parameters that are components of the CP classification
system, such as albumin, AST, ALT, bilirubin, and prothrom-
bin time, were explored. When axitinib plasma exposure
(indicated by plasma AUC) was assessed in relation to
measures of liver function, there were marginal trends for
axitinib AUC toincreasewithlower serum albumin (r
2=0.14;
p=0.0644), higher AST (r
2=0.10; p=0.1028), higher ALT
(r
2=0.02; p=0.4969), and higher bilirubin (r
2=0.13; p=
0.0710) (Fig. 3). Increased axitinib exposure was also
associated with higher prothrombin time (r
2=0.11; p=
0.1067). These trends did not reach statistical significance.
When axitinib AUC was evaluated according to smoking
respectively, for non-smokers, active smokers, and ex-
smokers (i.e., not actively smoking at the time of screening
who would refrain from smoking throughout the study
period). Weak correlations between the fraction unbound in
plasma of axitinib and both plasma albumin and bilirubin
concentrations were observed (data not shown).
Safety
Adverse events The 5-mg single dose of axitinib was well
tolerated in subjects with mild or moderate hepatic
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status, the median exposures were 200, 236, and 263 ng h/ml,impairment or normal hepatic function. There were no deaths,
serious adverse events, or discontinuations due to study
treatment. A total of four adverse events were reported in
three subjects in the group with normal hepatic function,
including headache (n=1) and lethargy (n=3). The three
adverse events of lethargy were considered to be treatment-
related, were mild or moderate in nature, and resolved
without treatment. No adverse events were reported in the
mild or moderate hepatic-impairment groups.
Laboratory parameters The incidence of laboratory abnor-
malities was low, and no clinically important trends were
observed. No laboratory abnormalities were reported as
adverse events. There were a total of 13 reports of
laboratory abnormalities, 8 of which were also reported at
baseline (2 with normal hepatic function, 3 with mild
hepatic impairment, and 8 with moderate hepatic impair-
ment). In the healthy-subject group, there was one report
each of urine white blood cell count ≥6/high power field
(HPF) and urine hyaline casts >1/low power field (LPF). In
the mild hepatic-impairment group, there was one report
each of urine protein ≥1, urine protein/hemoglobin ≥1,
and urine hyaline casts >1/LPF. In the moderate hepatic-
impairment group, there was one report each of eosinophil
% >1.2 times upper limit of normal (ULN), absolute
monocyte count 1.2 times ULN, urine white blood cell
count ≥6/HPF, urine glucose ≥1, urine hyaline casts >1/LPF,
and urine granular casts >1/LPF, and two reports of urine
protein ≥1.
Vital signs There were no clinically significant changes in
vital signs or ECGs. An increase in post-baseline systolic
and diastolic blood pressure was observed for some
subjects in the mild and moderate hepatic-impairment
groups (mean increases of 24.9 mm Hg and 14.8 mm Hg,
systolic and diastolic blood pressure, respectively, 16 h post
dosing), but blood pressures returned to near baseline levels
at the next collection time point on day 7. Transient and
reversible increases in blood pressure following axitinib
single-dose administration have been noted in previous
studies of healthy volunteers.
Discussion
The results from this study demonstrate three important
findings. First, moderate hepatic impairment increased the
exposure (AUC0 1 and Cmax) of axitinib compared with
normal hepatic function; however, mild hepatic impairment
did not change these pharmacokinetic parameters. Second,
there were no overt changes in plasma protein binding of
axitinib among the three subject groups. Third, a 5-mg
single oral dose of axitinib was well tolerated in subjects
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normal hepatic function.
The impact of hepatic impairment on the pharmacoki-
netics and disposition of drugs as well as on their efficacy
and tolerability is well known, and is of particular
importance in identifying patient populations that may be
at increased risk for toxicity. Both the FDA and the
European Medicines Agency have issued guidelines for
the evaluation of the pharmacokinetics of drugs in clinical
development in patients with impaired hepatic function [8,
15]. In this study, following administration of a 5-mg single
oral dose of axitinib, the pharmacokinetics was not affected
by mild hepatic impairment (CP-A). However, axitinib
plasma exposure was increased approximately two-fold by
moderate hepatic impairment (CP-B) compared with normal
hepatic function.
The primary route of elimination for axitinib is via
axitinib, and theoretical hepatic blood flow in humans) and
a high degree of plasma protein binding (>99% bound).
Based on the well-stirred model of hepatic clearance, the
hepatic clearance of a low-extraction drug would be
assumed to be the product of the intrinsic clearance and
fraction unbound in plasma [16–18]. For low-extraction
drugs with high plasma protein binding (≥90%), the free
fraction of drug is typically increased in patients with liver
cirrhosis, which is associated with an increase in plasma
clearance [19, 20]. No overt changes in protein binding of
axitinib in subjects with mild or moderate hepatic impair-
ment were observed in this study and, therefore, the changes
in exposure are likely due to a change in the intrinsic
clearance. This is probably associated with lowered meta-
bolic capacity in subjects with moderate impairment or
shunting of hepatic blood flow resulting in drug bypassing
the hepatic parenchymal cells (with metabolic enzymes).
Mechanisms for decreases in binding of drugs to plasma
proteins with hepatic impairment include (1) changes in
albumin synthesis, leading to lower levels of plasma
albumin, and (2) accumulation of endogenous compounds
such as bilirubin [21]. Expectedly, subjects with moderate
impairment in this study had higher baseline bilirubin
values compared with subjects in the mild-impairment
group. Also, subjects with moderate hepatic impairment
had lower serum baseline albumin levels compared with
subjects with mild impairment. However, this did not
translate into a meaningful change in plasma protein
binding for axitinib; there were no overt changes in fraction
unbound in plasma among the three groups assessed in the
study. Presumably the altered lab parameters for albumin
and bilirubin with hepatic impairment were not sufficient to
elicit a change in fraction unbound for a drug (e.g., axitinib)
that is highly protein bound (>99%). Further, the detection
of minor changes in protein binding may be limited by the
current bioanalytical methodology as well as the variability
seen in protein binding between subjects. In addition, weak
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hepatobiliary excretion. Axitinib has an estimated low
hepatic extraction ratio in humans (∼0.3, computed from
observed systemic clearance after an intravenous dose to
humans, experimentally observed blood-to-plasma ratio forcorrelations were found between axitinib exposure and
clinical laboratory parameters that are typical measures of
hepatic function, including AST, ALT, albumin, bilirubin,
and prothrombin time. Since axitinib is metabolized by
CYP1A2, albeit to a minor extent, relationships with
smoking status were also evaluated since smoking has
been shown to induce CYP1A2 [22]. Although only a small
number of patients were evaluated, the study results
indicated that axitinib exposure was similar in non-
smokers, active smokers, and ex-smokers. Smoking status
is being evaluated as a covariate for axitinib exposure in
ongoing population pharmacokinetic analyses from multi-
ple axitinib trials.
While the observed changes in axitinib pharmacoki-
netics with hepatic impairment did not precisely match
those predicted by Simcyp, they were in general agreement,
particularly for the moderate-impairment group. It should
be noted that the Simcyp predictions for axitinib
pharmacokinetics in subjects with normal hepatic func-
tion resulted in overprediction of the plasma exposures
compared with what is observed clinically. The reasons
for the differences between Simcyp-predicted and clini-
cally observed data could be ascribed to the selected
input parameters in the hepatic-impairment model used
by the software and built-in standard physiological
parameters used for the simulations. While the existing
input parameters based on in vitro data underestimated
the clinical plasma clearance for axitinib (Simcyp CL/F
was still able to reasonably predict the expected fold
change in exposures with hepatic impairment. Overall,
Simcyp-predicted 1.3- to 1.5-fold higher exposures ex-
pected with mild and moderate impairment and provided
confidence in the selection of a 5-mg single dose for this
c l i n i c a ls t u d yw h e ni tw a sb e i n gd e s i g n e d ,w h i c hw a s
based on the previous safe administration of up to six-fold
higher (i.e., 30 mg) single doses of axitinib in patients [6].
These results support the use of in silico modeling tools
such as Simcyp to aid in the design of clinical studies.
This study also demonstrated that a single dose of
axitinib was well tolerated in subjects with hepatic
impairment, with no adverse events reported in either the
mild- or moderate-impairment groups. Three treatment-
related adverse events were reported during this study, all of
which occurred in the group with normal hepatic function.
These were mild or moderate events and resolved without
further treatment. This study does not address the safety
and tolerability of axitinib in cancer patients with hepatic
impairment, but the data reported here may be used to
guide dosing in these patients.
While the exact change in axitinib plasma exposure antic-
ipated in subjects with severe hepatic impairment (CP-C)
was not evaluated in this study, it can be reasonably expected
to exceed or equal changes observed in subjects with
moderate hepatic impairment (CP-B). In ongoing studies of
axitinib in patients with solid tumors, subjects are required to
have adequate hepatic function at the time of study entry.
However, for patients who might develop hepatic impair-
ment during axitinib treatment, the results of this study
indicate the need for appropriate dose reduction, particularly
when the extent of hepatic impairment approaches moderate
impairment as defined by CP criteria. Ongoing studies in
cancer patients will provide guidance on appropriate dose
reductions for axitinib based on observed safety profiles of
individual patients. These study results indicate the need for
particular attention to dose adjustments in patients who
develop moderate (or worse) hepatic impairment.
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